Since indoleamine-pyrrole 2,3-dioxygenase (IDO1) upregulation was noted a major immunoinhibitory pathway upon combined radio- and immunotherapy in glioma patients, Ladomersky et al. [203] evaluated IDO1 inhibition with radiation and PD-1 inhibition [203,204]. This evidence concerns the gene IDO1 and central nervous system cancer.